{"DataElement":{"publicId":"3755631","version":"1","preferredName":"Chronic Graft Versus Host Disease Other Diagnostic Feature Name","preferredDefinition":"Text term to identify a diagnostic characteristic of chronic Graft versus Host Disease (cGVHD) that is different than a set of options.","longName":"CGVHD_OTX_DIAG_FT_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3755433","version":"1","preferredName":"Chronic Graft Versus Host Disease Other Diagnostic Characteristic","preferredDefinition":"The assessment of the transplant recipient for signs and symptoms of chronic Graft versus Host Disease (GVHD)._An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Different than the one(s) previously specified or mentioned._Supplying or being a final or conclusive settlement or result.__Characteristic or indicative of (e.g., a disease).","longName":"CGVHD_OTX_DIAG_FEAT","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2676585","version":"1","preferredName":"Chronic Graft Versus Host Disease","preferredDefinition":"A disease or condition that persists or progresses over a long period of time.:An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.","longName":"C14141:C3063","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic","conceptCode":"C14141","definition":"Usually used to describe a condition that is persistent and long standing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3951A8C0-249F-64ED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-04","modifiedBy":"ONEDATA","dateModified":"2007-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3755431","version":"1","preferredName":"Other Diagnostic Characteristic","preferredDefinition":"Different than the one(s) previously specified or mentioned.:Characteristic or indicative of (e.g., a disease).:Characteristics; distinguishing qualities of a person, object, or substance.","longName":"C17649:C25482:C25447","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Diagnostic","conceptCode":"C25482","definition":"Characteristic or indicative of a condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Characteristic","conceptCode":"C25447","definition":"The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC3A08ED-01C9-0C62-E040-BB89AD431C92","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC3A08ED-01DA-0C62-E040-BB89AD431C92","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3755612","version":"1","preferredName":"Chronic Graft Versus Host Disease Other Diagnostic Feature Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"CGHVD_OTX_DIAG_FT_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Blepharitis","valueDescription":"Blepharitis","ValueMeaning":{"publicId":"3755613","version":"1","preferredName":"Blepharitis","longName":"3755613","preferredDefinition":"Inflammation of the eyelids and eyelashes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-99E3-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-99FC-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Periorbital hyperpigmentation","valueDescription":"Periorbital Skin Hyperpigmentation","ValueMeaning":{"publicId":"3755614","version":"1","preferredName":"Periorbital Skin Hyperpigmentation","longName":"3755614","preferredDefinition":"Occurring in, or located in the area around the orbit of the eye.: Darkening of the skin due to excessive melanin deposition. Causes include skin injuries, pregnancy, eczema, and Addison disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Periorbital","conceptCode":"C98190","definition":"Occurring in, or located in the area around the orbit of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Skin Hyperpigmentation","conceptCode":"C79731","definition":"Darkening of the skin due to excessive melanin deposition. Causes include skin injuries, pregnancy, eczema, and Addison disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-9A09-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9A22-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Photophobia","valueDescription":"Photophobia","ValueMeaning":{"publicId":"3123782","version":"1","preferredName":"Photophobia","longName":"3123782","preferredDefinition":"A disorder characterized by fear and avoidance of light.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Photophobia","conceptCode":"E10416","definition":"A disorder characterized by fear and avoidance of light.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC4736B-27C3-40DF-E040-BB89AD435D6D","latestVersionIndicator":"Yes","beginDate":"2010-07-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-07-19","modifiedBy":"ONEDATA","dateModified":"2010-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9A2C-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Premature gray hair","valueDescription":"Early Gray Hair","ValueMeaning":{"publicId":"3755616","version":"1","preferredName":"Early Gray Hair","longName":"3755616","preferredDefinition":"At or near the beginning of a period of time or course of events.: An achromatic color of any lightness between the extremes of black and white.: The filamentous outgrowth of the epidermis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Early","conceptCode":"C61589","definition":"At or near the beginning of a period of time or course of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gray","conceptCode":"C48324","definition":"An achromatic color of any lightness between the extremes of black and white.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hair","conceptCode":"C32705","definition":"The filamentous outgrowth of the epidermis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-9A3C-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9A55-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Thinning scalp hair, typically patchy, coarse, or dull","valueDescription":"Thinning scalp hair","ValueMeaning":{"publicId":"3755617","version":"1","preferredName":"Thinning scalp hair","longName":"3755617","preferredDefinition":"Thinning scalp hair","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-9A5F-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9A78-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Hypopigmentation","valueDescription":"Skin Hypopigmentation","ValueMeaning":{"publicId":"2944642","version":"1","preferredName":"Skin Hypopigmentation","longName":"2944642","preferredDefinition":"Loss of skin pigment. Vitiligo, albinism, and leukoderma are among the disorders that are associated with skin hypopigmentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Hypopigmentation","conceptCode":"C78610","definition":"Abnormal lightening of skin due to decreased melanin production or deposition. Vitiligo, albinism, and leukoderma are among the disorders that are associated with skin hypopigmentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7440E944-6947-CDD0-E040-BB89AD431DF0","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9A8C-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Hyperpigmentation","valueDescription":"Skin Hyperpigmentation","ValueMeaning":{"publicId":"2944640","version":"1","preferredName":"Skin Hyperpigmentation","longName":"2944640","preferredDefinition":"Darkening of the skin due to excessive melanin deposition. Causes include skin injuries, pregnancy, eczema, and Addison disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Hyperpigmentation","conceptCode":"C79731","definition":"Darkening of the skin due to excessive melanin deposition. Causes include skin injuries, pregnancy, eczema, and Addison disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7440E944-6921-CDD0-E040-BB89AD431DF0","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9AA1-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Keratosis pilaris","valueDescription":"Keratosis pilaris","ValueMeaning":{"publicId":"2585192","version":"1","preferredName":"Keratosis pilaris","longName":"2585192","preferredDefinition":"Keratosis pilaris","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26809F27-C2F4-70B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-08","modifiedBy":"KUMMEROA","dateModified":"2022-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9AAC-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Ichthyosis","valueDescription":"Ichthyosis","ValueMeaning":{"publicId":"3211170","version":"1","preferredName":"Ichthyosis","longName":"3211170","preferredDefinition":"A group of inherited or acquired skin disorders characterized by a dry, thickened, and scaly skin. The skin changes range from mild to severe.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ichthyosis","conceptCode":"C84776","definition":"A group of inherited or acquired skin disorders characterized by a dry, thickened, and scaly skin. The skin changes range from mild to severe.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D7CF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9AB7-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Sweat impairment","valueDescription":"Sweat Impairment","ValueMeaning":{"publicId":"3755618","version":"1","preferredName":"Sweat Impairment","longName":"3755618","preferredDefinition":"The liquid secreted by the sweat glands, having a salty taste and a pH that varies from 4.5 to 7.5. Sweat produced by the eccrine sweat glands is clear with a faint characteristic odor, and contains water, sodium chloride, and traces of albumin, urea, and other compounds. Its composition varies with many factors, e.g., fluid intake, external temperature and humidity, and some hormonal activity. Sweat produced by the larger, deeper, apocrine sweat glands of the axillae contains, in addition, organic material which on bacterial decomposition produces an offensive odor.: Loss or abnormality of psychological, physiological, or anatomic structure or function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sweat","conceptCode":"C13280","definition":"The liquid secreted by the sweat glands, having a salty taste and a pH that varies from 4.5 to 7.5. Sweat produced by the eccrine sweat glands is clear with a faint characteristic odor, and contains water, sodium chloride, and traces of albumin, urea, and other compounds. Its composition varies with many factors, e.g., fluid intake, external temperature and humidity, and some hormonal activity. Sweat produced by the larger, deeper, apocrine sweat glands of the axillae contains, in addition, organic material which on bacterial decomposition produces an offensive odor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Impairment","conceptCode":"C21055","definition":"Loss or abnormality of psychological, physiological, or anatomic structure or function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-9AC5-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC411577-9ADE-49BE-E040-BB89AD434EFB","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"Arthralgia or arthritis","valueDescription":"Arthralgia Or Arthritis Symptom","ValueMeaning":{"publicId":"3766431","version":"1","preferredName":"Arthralgia Or Arthritis Symptom","longName":"3766431","preferredDefinition":"A disorder characterized by a sensation of marked discomfort in a joint.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.: Subjective evidence of disease perceived by the patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthralgia","conceptCode":"E12374","definition":"A disorder characterized by a sensation of marked discomfort in a joint.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Arthritis","conceptCode":"C2883","definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Symptom","conceptCode":"C4876","definition":"Subjective evidence of disease perceived by the patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCED4AE8-E192-33A5-E040-BB89AD430FDC","latestVersionIndicator":"Yes","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCED4AE8-E1AB-33A5-E040-BB89AD430FDC","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"ONEDATA","dateModified":"2013-05-17","deletedIndicator":"No"},{"value":"Muscle cramps","valueDescription":"Muscle Cramp","ValueMeaning":{"publicId":"3766432","version":"1","preferredName":"Muscle Cramp","longName":"3766432","preferredDefinition":"A sustained and usually painful contraction of muscle fibers. This may occur as an isolated phenomenon or as a manifestation of an underlying disease process (e.g., UREMIA; HYPOTHYROIDISM; MOTOR NEURON DISEASE; etc.). (From Adams et al., Principles of Neurology, 6th ed, p1398)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muscle Cramp","conceptCode":"C34827","definition":"A sustained, sudden and involuntary contraction of a muscle or group of muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCED4AE8-E1B5-33A5-E040-BB89AD430FDC","latestVersionIndicator":"Yes","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCED4AE8-E1CE-33A5-E040-BB89AD430FDC","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"ONEDATA","dateModified":"2013-05-17","deletedIndicator":"No"},{"value":"Edema","valueDescription":"Edema","ValueMeaning":{"publicId":"3637928","version":"1","preferredName":"Edema","longName":"3637928","preferredDefinition":"Accumulation of an excessive amount of watery fluid in cells or intercellular tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Edema","conceptCode":"C3002","definition":"Accumulation of an excessive amount of fluid in cells or intercellular tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0209A7E-B986-D19B-E040-BB89AD432DDA","latestVersionIndicator":"Yes","beginDate":"2012-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCED4AE8-E1D8-33A5-E040-BB89AD430FDC","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"ONEDATA","dateModified":"2013-05-17","deletedIndicator":"No"},{"value":"Pericardial or pleural effusions","valueDescription":"Pericardial or pleural effusions","ValueMeaning":{"publicId":"3860653","version":"1","preferredName":"Pericardial or pleural effusions","longName":"3860653","preferredDefinition":"Of or pertaining to the pleura.: Located around the heart or relating to or affecting the pericardium.: A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural","conceptCode":"C25223","definition":"Of or pertaining to the pleura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pericardial","conceptCode":"C38001","definition":"Located around the heart or relating to or affecting the pericardium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Effusion","conceptCode":"C3003","definition":"A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4697DB6-3F9F-DAA4-E040-BB89AD434B4A","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-379E-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Cardiac conduction abnormality or cardiomyopathy","valueDescription":"Cardiac conduction abnormality or cardiomyopathy","ValueMeaning":{"publicId":"5487962","version":"1","preferredName":"Cardiac conduction abnormality or cardiomyopathy","longName":"5487962","preferredDefinition":"A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.: A disorder affecting the conduction system that sends electrical signals in the myocardium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiomyopathy","conceptCode":"C34830","definition":"A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cardiac Conduction Disorder","conceptCode":"C78245","definition":"A disorder affecting the conduction system that sends electrical signals in the myocardium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D980294-37AC-1D47-E053-F662850AABE7","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-37C5-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Autoantibodies (AIHA and ITP)","valueDescription":"Autoantibody","ValueMeaning":{"publicId":"2793852","version":"1","preferredName":"Autoantibody","longName":"2793852","preferredDefinition":"Abnormal immunoproteins that act against the body's own tissues because they have been mistakenly identified as being foreign.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoantibody","conceptCode":"C48966","definition":"An antibody acting against tissues of the organism that produces it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"594ACCA7-6202-720E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-10-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-37CF-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Thrombocytopenia","valueDescription":"Thrombocytopenia","ValueMeaning":{"publicId":"2569502","version":"1","preferredName":"Thrombocytopenia","longName":"2569502v1.00","preferredDefinition":"A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombocytopenia","conceptCode":"C3408","definition":"A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CLOHNES","dateModified":"2023-05-17","changeDescription":null,"administrativeNotes":"5/17/23 Added C3408 per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-37D9-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Eosinophilia","valueDescription":"Eosinophilia","ValueMeaning":{"publicId":"2793850","version":"1","preferredName":"Eosinophilia","longName":"2793850","preferredDefinition":"A condition in which the number of eosinophils (a type of white blood cell) in the blood is greatly increased. Eosinophilia is often a response to infection or allergens (substances that cause an allergic response).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eosinophilia","conceptCode":"C3015","definition":"Abnormal high level of eosinophils in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"594ACCA7-61B4-720E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-10-15","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-37E4-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Lymphopenia","valueDescription":"Lymphopenia","ValueMeaning":{"publicId":"2945689","version":"1","preferredName":"Lymphopenia","longName":"2945689","preferredDefinition":"An abnormally small number of lymphocytes in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphopenia","conceptCode":"C26823","definition":"An abnormally small number of lymphocytes in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"745580E8-4998-8FA9-E040-BB89AD433702","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-37F8-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Hypogammaglobulinemia","valueDescription":"Hypogammaglobulinemia","ValueMeaning":{"publicId":"4276835","version":"1","preferredName":"Hypogammaglobulinemia","longName":"4276835","preferredDefinition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypogammaglobulinemia","conceptCode":"C26931","definition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7A209D6-790C-98DB-E040-BB89AD4339B1","latestVersionIndicator":"Yes","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-3803-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Hypergammaglobulinemia","valueDescription":"Hypergammaglobulinemia","ValueMeaning":{"publicId":"5487963","version":"1","preferredName":"Hypergammaglobulinemia","longName":"5487963","preferredDefinition":"An excess of GAMMA-GLOBULINS in the blood. It is seen frequently in chronic infectious diseases. (Dorland, 27th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypergammaglobulinemia","conceptCode":"C34705","definition":"A laboratory test result indicating abnormally high concentrations of gamma globulins in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D980294-380F-1D47-E053-F662850AABE7","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-3828-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Ascites","valueDescription":"Ascites","ValueMeaning":{"publicId":"3777378","version":"1","preferredName":"Ascites","longName":"3777378","preferredDefinition":"Accumulation of fluid in the peritoneal cavity.  The fluid may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peritoneal Effusion","conceptCode":"C2885","definition":"The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED0A0C3-6812-5026-E040-BB89AD4335C1","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-3847-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Peripheral Neuropathy","valueDescription":"Peripheral Neuropathy","ValueMeaning":{"publicId":"2573570","version":"1","preferredName":"Peripheral Neuropathy","longName":"2573570","preferredDefinition":"Peripheral Neuropathy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC6F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2005-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-3852-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Nephrotic Syndrome","valueDescription":"Nephrotic Syndrome","ValueMeaning":{"publicId":"3766434","version":"1","preferredName":"Nephrotic Syndrome","longName":"3766434","preferredDefinition":"Clinical association of heavy PROTEINURIA, HYPOALBUMINEMIA, and generalized EDEMA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nephrotic Syndrome","conceptCode":"C34845","definition":"A collection of symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCED4AE8-E22D-33A5-E040-BB89AD430FDC","latestVersionIndicator":"Yes","beginDate":"2013-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-17","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-385D-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Myasthenia Gravis","valueDescription":"Myasthenia Gravis","ValueMeaning":{"publicId":"3143924","version":"1","preferredName":"Myasthenia Gravis","longName":"3143924","preferredDefinition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness.  It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myasthenia Gravis","conceptCode":"C60989","definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167B9F7-3DD6-C748-E040-BB89AD432898","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-3867-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Restrictive Lung Disease","valueDescription":"Restrictive Lung Disease","ValueMeaning":{"publicId":"5487964","version":"1","preferredName":"Restrictive Lung Disease","longName":"5487964","preferredDefinition":"Decreased lung volume and inadequate ventilation due to parenchymal lung disorders (e.g., interstitial pulmonary fibrosis) or extrapulmonary disorders (e.g., scoliosis).  Patients present with shortness of breath and cough.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Restrictive Lung Disease","conceptCode":"C91762","definition":"Decreased lung volume and inadequate ventilation due to parenchymal lung disorders (e.g., interstitial pulmonary fibrosis) or extrapulmonary disorders (e.g., scoliosis).  Patients present with shortness of breath and cough.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D980294-3873-1D47-E053-F662850AABE7","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-388C-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Cryptogenic Organizing Pneumonia","valueDescription":"Cryptogenic Organizing Pneumonia","ValueMeaning":{"publicId":"2804712","version":"1","preferredName":"Cryptogenic Organizing Pneumonia","longName":"2804712","preferredDefinition":"A disease formerly considered a form of interstitial pneumonia. Its etiology is obscure but it may be associated with toxic fumes, infection, and connective tissue disease. Clinical symptoms include cough, dyspnea and influenza-like symptoms with the development of the usual interstitial pneumonia in many cases. Obstructive symptoms are limited to smokers. There are patchy polypoid masses of intra-alveolar granulation tissue in small airway lumina and alveolar ducts. \"Organizing\" refers to unresolved pneumonia (in which the alveolar exudate persists and eventually undergoes fibrosis) in which fibrous tissue forms in the alveoli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cryptogenic Organizing Pneumonia","conceptCode":"C62586","definition":"A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C7576B8-1938-1506-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-38A0-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Raynaud's Phenomenon","valueDescription":"Raynaud Phenomenon","ValueMeaning":{"publicId":"4395150","version":"1","preferredName":"Raynaud Phenomenon","longName":"4395150","preferredDefinition":"An episodic vasoconstriction resulting in discoloration of the skin and pain in the affected areas, often involving fingers or toes. Classically associated with triphasic color changes (white, blue, red) but may be biphasic. Often occurs in response to cold temperatures or emotional stress. May be primary or secondary to an underlying autoimmune disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raynaud Phenomenon","conceptCode":"C50724","definition":"An episodic vasoconstriction resulting in discoloration of the skin and pain in the affected areas, often involving fingers or toes. Classically associated with triphasic color changes (white, blue, red) but may be biphasic. Often occurs in response to cold temperatures or emotional stress. May be primary or secondary to an underlying autoimmune disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB64B44-1A50-30C0-E040-BB89AD435920","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D980294-38CE-1D47-E053-F662850AABE7","beginDate":"2016-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Exocrine pancreatic insufficiency","valueDescription":"Pancreatic Insufficiency","ValueMeaning":{"publicId":"2955753","version":"1","preferredName":"Pancreatic Insufficiency","longName":"2955753","preferredDefinition":"Inability of the exocrine pancreas to produce and secrete an adequate amount of digestive enzymes into the small intestine.  Patients present with symptoms of malabsorption syndrome, abdominal discomfort, and bloating.  Causes include chronic pancreatitis, cystic fibrosis, and autoimmune disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Insufficiency","conceptCode":"C84316","definition":"Inability of the exocrine pancreas to produce and secrete an adequate amount of digestive enzymes into the small intestine.  Patients present with symptoms of malabsorption syndrome, abdominal discomfort, and bloating.  Causes include chronic pancreatitis, cystic fibrosis, and autoimmune disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"769BA032-1319-045A-E040-BB89AD431EE2","latestVersionIndicator":"Yes","beginDate":"2009-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3691E92-8856-3019-E053-F662850A01B7","beginDate":"2020-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC411577-99D0-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"COOPERM","dateModified":"2020-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Other Diagnostic Feature","type":"Preferred Question Text","description":"Other Diagnostic Feature","url":null,"context":"CCR"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Other features related to CGVHD:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DC411577-9AE8-49BE-E040-BB89AD434EFB","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-08","modifiedBy":"MAESKEB","dateModified":"2022-03-31","changeDescription":"Curated to support NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}